Scarica l'app Stockscreener
2.48
1.20%
-0.03
Dopo l'orario di chiusura:
2.50
0.02
+0.81%
Precedente Chiudi:
$2.51
Aprire:
$2.5
Volume 24 ore:
113.24K
Relative Volume:
0.02
Capitalizzazione di mercato:
$37.50M
Reddito:
$2.09M
Utile/perdita netta:
$-30.04M
Rapporto P/E:
-0.7588
EPS:
-3.2685
Flusso di cassa netto:
$-27.57M
1 W Prestazione:
-2.36%
1M Prestazione:
-13.29%
6M Prestazione:
-48.97%
1 anno Prestazione:
-73.95%
Intervallo 1D:
$2.47
$2.53
Intervallo di 1 settimana:
$2.4199
$2.58
Portata 52W:
$2.13
$10.00
Cervomed Inc Stock (CRVO) Company Profile
Nome
Cervomed Inc
Settore
Industria
Telefono
(617) 744-4400
Indirizzo
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
2.48 | 37.95M | 2.09M | -30.04M | -27.57M | -3.2685 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-12-05 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-18 | Iniziato | Chardan Capital Markets | Buy |
| 2024-07-26 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-15 | Iniziato | Canaccord Genuity | Buy |
| 2020-11-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cervomed Inc Borsa (CRVO) Ultime notizie
CervoMed (NASDAQ: CRVO) data accepted for late-breaking dementia conference talk - Stock Titan
CervoMed to present neflamapimod trial data at ISFTD - grafa.com
CervoMed to present nfvPPA trial biomarker data at ISFTD meeting By Investing.com - Investing.com Canada
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 - Yahoo Finance
CervoMed's neflamapimod wins UK ILAP Innovation Passport for DLB - scanx.trade
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - Stocktwits
CervoMed to Participate in September Investor Conferences - Yahoo! Finance Canada
CRVO News | CERVOMED INC (NASDAQ:CRVO) - ChartMill
CervoMed Company Profile & Introduction - Moomoo
CervoMed (CRVO) Results Review: EPS Exceeds Its Estimate in the Latest Session; Price Reaction: The Market Price Advances 2.34% at the CloseSubscription Growth Report - dars.gov.et
ARMISTICE CAPITAL, LLC Acquires New Stake in CervoMed Inc (CRVO) - GuruFocus
Roth MKM Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
SABBY MANAGEMENT, LLC's CervoMed Inc(CRVO) Holding History - GuruFocus
CRVO Q2 2026 Earnings: Loss Narrows 27.7% vs Estimates, Shares Dip 6.8%Earnings Cycle Outlook - vinanet.vn
CervoMed (CRVO): RA Capital discloses 8.6% stake through 1.27M warrant shares - Stock Titan
CervoMed (CRVO) holders CVI and Heights report 0% stake in amended filing - Stock Titan
Woodline Partners (CRVO) discloses 5.1% beneficial stake in CervoMed common stock - Stock Titan
Armistice Capital discloses 9.53% CervoMed (CRVO) ownership via Master Fund - Stock Titan
CRVO Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.64 Beats Estimates by 27.7%; Shares Slip 4.56% - vinanet.vn
CRVO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $18 - Moomoo
CervoMed at Canaccord Genuity conference: dLB push gains ground By Investing.com - Investing.com Nigeria
CRVO: Phase III-ready DLB drug shows strong clinical data; pipeline expands into PPA and ALS - TradingView
CervoMed at Canaccord Genuity conference: dLB push gains ground - Investing.com
CervoMed Inc. (CRVO) Surges 9% as Biotech Stock Approaches Key Resistance at $3.28Stop Loss Guidance - dars.gov.et
JonesTrading Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
CervoMed reports Q2 2026: $24.9M cash position, net loss $6.6M; advancing neflamapimod toward Phase 3 - TradingView
CervoMed (NASDAQ: CRVO) details Q2 2026 loss, cash runway and DLB program - Stock Titan
Canaccord cuts CervoMed stock price target on funding uncertainty By Investing.com - Investing.com India
CervoMed presents data on DLB treatment at AAIC 2026 - scanx.trade
CRVO Maintained by Canaccord Genuity -- Price Target Lowered to $18 - GuruFocus
CervoMed Q2 Results: EPS Misses Estimate, Losses Widen YoY - scanx.trade
CervoMed Q2 Results: Net Loss Widens To $6.6M, Seeks DLB Partner - scanx.trade
Canaccord cuts CervoMed stock price target on funding uncertainty - Investing.com
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
CervoMed Q2 net loss lower than estimates as costs drop - TradingView
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $18 - Moomoo
CRVO Q2'26 Earnings: revenue estimate is 50.00K USD - TradingView
CERVOMED INC : CANACCORD GENUITY CUTS TARGET PRICE TO $18 FROM $27 - Bitget
CRVO Q2 2026 Earnings: Loss of -$0.64 Beats Estimates by 27.74% but No Revenue ReportedTangible Book Value - vinanet.vn
CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely - simplywall.st
CervoMed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CervoMed Inc. 2026: Revenue $0 Net income ($6.57M), EPS ($0.64) — 10-Q Summary - TradingView
CRVO: Raised $20.5M in June 2026 to fund R&D and strategic partnership for Phase 3 DLB trial - TradingView
CervoMed (NASDAQ: CRVO) raises $20.5M, ends Q2 with $24.9M cash - Stock Titan
CRVO: Neflamapimod progresses to Phase 3 for DLB, with strong cash position and key milestones ahead - TradingView
CervoMed Inc (CRVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CervoMed Inc. (CRVO) Edges Lower to $2.77 as Shares Consolidate Within Tight Trading RangeQuality Factor - dars.gov.et
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - manilatimes.net
CervoMed Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
CervoMed granted UK Innovation Passport for neflamapimod in dementia with Lewy bodies - TradingView
Cervomed Inc Azioni (CRVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):